Novanta (NASDAQ:NOVT – Get Free Report) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $3.02-3.06 for the period, compared to the consensus earnings per share estimate of $3.29. The company issued revenue guidance of ~$948-953 million, compared to the consensus revenue estimate of $973.07 million. Novanta also updated its FY 2024 guidance to 3.020-3.060 EPS.
Analysts Set New Price Targets
Separately, Robert W. Baird lifted their price objective on Novanta from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th.
Check Out Our Latest Stock Analysis on NOVT
Novanta Trading Down 5.4 %
Novanta (NASDAQ:NOVT – Get Free Report) last issued its earnings results on Tuesday, August 6th. The technology company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.04. The business had revenue of $235.86 million during the quarter, compared to analysts’ expectations of $233.63 million. Novanta had a return on equity of 15.77% and a net margin of 6.91%. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.80 EPS. On average, sell-side analysts anticipate that Novanta will post 3.3 EPS for the current fiscal year.
Insider Activity at Novanta
In other news, CFO Robert Buckley sold 1,111 shares of the business’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $180.45, for a total transaction of $200,479.95. Following the transaction, the chief financial officer now directly owns 120,419 shares of the company’s stock, valued at approximately $21,729,608.55. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 9,150 shares of company stock worth $1,608,936. Corporate insiders own 1.20% of the company’s stock.
About Novanta
Novanta Inc, together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation.
Recommended Stories
- Five stocks we like better than Novanta
- High Flyers: 3 Natural Gas Stocks for March 2022
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Insider Buying Signals Upside for These 3 Stocks
- What is Short Interest? How to Use It
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.